Cardiomyopathy in muscular dystrophy: When to treat?

JAMA Cardiology

Volumn 2, Issue 2, 2017, Pages 199-

  McNally, Elizabeth M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; EPLERENONE;

ADOLESCENT; CARDIOVASCULAR MAGNETIC RESONANCE; COHORT ANALYSIS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; EDITORIAL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HUMAN; MAJOR CLINICAL STUDY; PERSONALIZED MEDICINE; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; CARDIOMYOPATHY;

CARDIOMYOPATHIES; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 85031308307     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.4910     Document Type: Editorial

References (4)

1. Silva MC, Magalhães TA, Meira ZMA, et al. Myocardial fibrosis progression in Duchenne and Becker muscular dystrophy: a randomized clinical trial [published online December 7, 2016]. JAMA Cardiol. doi:10.1001/jamacardio.2016.4801
2. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Bécane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol. 2005;45(6):855-857.
3. Raman SV, Hor KN, Mazur W, et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14(2): 153-161.
4. McNally EM, Kaltman JR, Benson DW, et al; Working Group of the National Heart, Lung, and Blood Institute; Parent Project Muscular Dystrophy. Contemporary cardiac issues in Duchenne muscular dystrophy. Circulation. 2015;131(18):1590-1598.